gefitinib has been researched along with cadaverine in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (cadaverine) | Trials (cadaverine) | Recent Studies (post-2010) (cadaverine) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,276 | 3 | 341 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bally, MB; Donohue, E; Dragowska, WH; Gelmon, KA; Gorski, SM; Kapanen, AI; Qadir, MA; Rawji, JS; Roberge, M; Wang, JC; Warburton, C; Weppler, SA; Wong, LY | 1 |
1 other study(ies) available for gefitinib and cadaverine
| Article | Year |
|---|---|
Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Beclin-1; Breast Neoplasms; Cadaverine; Cell Line, Tumor; Cell Survival; Cytoplasmic Vesicles; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Gene Silencing; Humans; Hydroxychloroquine; Membrane Proteins; Mice; Phagosomes; Quinazolines; RNA, Small Interfering; Signal Transduction; Staining and Labeling; Tamoxifen; Treatment Outcome; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays | 2013 |